Drug repositioning of endogenous regenerative factor inducers
First written in FY2023. 8 of 11 entries say "Advanced", first in FY2024-Q3. Latest entry: 2026-08-13.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「While extending the joint research period with Niigata University on liver diseases and compiling the results, we began a second phase of joint research with the Division of Gastroenterological Surgery at Osaka University after its results were published in an international academic journal. We also continued research on intestinal diseases with the Division of Gastroenterology and Hepatology. From a business-development perspective, we are pursuing activities to collaborate with and out-license to pharmaceutical companies and others through partnering events, with the aim of early commercialization and maximizing value, and are continuing specific discussions.」
In addition to continuing and extending liver-disease research, the company advanced to publication of results from Osaka University’s gastroenterological surgery division, the start of a second-phase joint study, continued intestinal-disease research, and discussions with pharmaceutical companies and others regarding out-licensing. - FY2026-H1AdvancedAnnual report
「We are conducting joint research with Osaka University on cirrhosis, liver resection and other conditions. During the interim consolidated accounting period under review, Osaka University published a research paper on cirrhosis. The paper indicated that the treatment could be a promising option for liver fibrosis caused by cirrhosis.」
A paper was published from the joint liver-disease research with Osaka University, and the company explained that it indicated promise as a treatment for liver fibrosis. - FY2024RestatedAnnual report
「Because the treatment uses a very low dose of the oxime derivative, one of its characteristics is that safety can be ensured. The project also involves drug repositioning using an already developed compound and aims to achieve efficient development and commercialization.」
The policy of efficient development and commercialization through drug repositioning using YS-1301 continued. - FY2024-Q3AdvancedAnnual report
「During the cumulative third-quarter period under review, development of a synthesis method toward industrial-scale manufacturing reached a clear path. In addition to exploratory research with Osaka University, we are conducting joint research with Niigata University using animal models of liver diseases such as cirrhosis and non-alcoholic steatohepatitis (NASH) to confirm effects including suppression of inflammation and fibrosis and improvement of liver function.」
For YS-1301, development of a synthesis method toward industrial-scale manufacturing reached a clear path. Joint research with Niigata University using liver-disease animal models was also under way. - FY2024-Q1RestatedAnnual report
「We completed the transfer of substance patents and know-how from ONO PHARMACEUTICAL CO.,LTD. and 株式会社カルディオ, and are proceeding with validation of mechanisms of action and formulation development for the target diseases. In addition to ongoing exploratory research with Osaka University, we entered into an agreement with Nagoya University regarding the provision of the drug. We are also preparing exploratory research by multiple academic institutions while searching for development partners in parallel.」
For YS-1301, the company continued validating the mechanism of action and developing formulations after the transfer of intellectual property and know-how, while advancing exploratory research with academic institutions and searching for development partners. - FY2023First statedAnnual report
「This project involves drug repositioning, using a compound that has already been developed, and aims to achieve efficient development and commercialization.」
The project uses the oxime derivative YS-1301 for cirrhosis/NASH, ASO, CKD, COPD and other conditions. Transfers of patents and know-how have been completed, and the company is proceeding with validation of mechanisms of action, formulation development, academic research and the search for development partners.